PMID- 25678772
OWN - NLM
STAT- MEDLINE
DCOM- 20150909
LR  - 20221207
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 9
DP  - 2015
TI  - Emerging options for the treatment of type 2 diabetes in Chinese patients: focus 
      on arterial function and alogliptin.
PG  - 683-6
LID - 10.2147/DDDT.S53048 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has become a worldwide health problem, and the 
      rate of it is growing greatly in the People's Republic of China every year. T2DM 
      could cause macrovascular and microvascular complications that lead to an 
      increase in arterial wall thickness, endothelial dysfunction, calcification, and 
      - finally - to an increase in arterial stiffness and arterial dysfunction. 
      Alogliptin, a new selective inhibitor of dipeptidyl peptidase 4, has shown its 
      great antihyperglycemia effect in T2DM patients. The clinical trial data from the 
      People's Republic of China was similar to other global and Asian trials. This 
      could provide some choice for clinical physicians to the treatment of T2DM.
FAU - Wang, Hongyu
AU  - Wang H
AD  - Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, 
      People's Republic of China.
FAU - Liu, Jinbo
AU  - Liu J
AD  - Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, 
      People's Republic of China.
FAU - Zhao, Hongwei
AU  - Zhao H
AD  - Department of Vascular Medicine, Peking University Shougang Hospital, Beijing, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150130
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Piperidines)
RN  - 56HH86ZVCT (Uracil)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
RN  - JHC049LO86 (alogliptin)
SB  - IM
MH  - Animals
MH  - Arteries/*drug effects/enzymology/physiopathology
MH  - *Asian People
MH  - China/epidemiology
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug 
      therapy/enzymology/ethnology/physiopathology
MH  - Diabetic Angiopathies/diagnosis/*drug 
      therapy/enzymology/ethnology/physiopathology
MH  - Dipeptidyl Peptidase 4/*metabolism
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Humans
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Uracil/adverse effects/*analogs & derivatives/therapeutic use
MH  - Vascular Stiffness/*drug effects
PMC - PMC4322603
OTO - NOTNLM
OT  - People's Republic of China
OT  - alogliptin
OT  - arterial function
OT  - type 2 diabetes mellitus
EDAT- 2015/02/14 06:00
MHDA- 2015/09/10 06:00
PMCR- 2015/01/30
CRDT- 2015/02/14 06:00
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2015/09/10 06:00 [medline]
PHST- 2015/01/30 00:00 [pmc-release]
AID - dddt-9-683 [pii]
AID - 10.2147/DDDT.S53048 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2015 Jan 30;9:683-6. doi: 10.2147/DDDT.S53048. eCollection 
      2015.